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but requires some attempts. Transesophageal
echocardiography confirmed right pump
placement and no interference between
valve leaflet movements and outflow-tip
antegrade flow. A trivial aortic regurgita-
tion was detected, probably because of the
relative stiffness of prosthetic compared
with natural valve leaflets. The postopera-
tive course was characterized by persistent
oliguria that required central veno–venous
haemofiltration, with slow improvement of
cardiac function. Inotropic support was
continued for 6 days and then slowly de-
creased. After 15 days of support, the pa-
tient was weaned from the device and
discharged home. Follow-up echocardi-
ography showed markedly improved left
ventricular contractility and good perfor-
mance of the aortic valve without signs of
damage to the leaflets.4
We agree with the author that in the set-
ting of postcardiotomy heart failure, deciding
when to start a patient on mechanical support
without wasting any precious time is the key
to success. Recently, we have introduced in
our clinical practice the IABP score as a
very useful tool in the decision-making
process of mechanical support in postcar-
diotomy heart failure. Hausmann and col-
leagues3 defined an IABP score based on 4
parameters they found statistically signifi-
cant to predict survival or death 1 hour
after IABP implantation in patients with
low-output syndrome in cardiac surgery.
The Hausmann IABP score has been vali-
dated also by Siegenthaler and associates5
in their study of 24 patients supported with
the Impella LD for postcardiotomy heart
failure. In addition, they were able to iden-
tify patients who will not benefit from the
Impella Recover. Patients with a residual
cardiac function of 1 L/min or less had an
88% chance of death. This observation is
likely due to the fact that the Impella de-
vice provides insufficient support in the
presence of virtually absent myocardial
function.
In conclusion, we agree with the au-
thors that timely insertion of such a device
in the postcardiotomy setting, even in bor-
derline situations or after stented biologic
aortic valve prosthesis implantation, can
provide a greater chance of survival in a
poor-prognosis population. Careful clini-
cal, hemodynamic, and residual cardiac
function evaluation can allow surgeons
to stratify patients for prolonged IABP-
inotropic support or timely Impella implan-
tation or even to receive a conventional left
ventricular assist device if cardiac perfor-
mance is dismal.
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Off-pump pulmonary valve
implantation
To the Editor:
We would like to comment on the article
by Berdat and Carrel1 entitled “Off-pump
pulmonary valve replacement with the
new Shelhigh Injectable Stented Pulmonic
Valve.” They are to be congratulated for
having embarked on a novel approach.
Because we have also reported recently
on our first surgical experience implanting
the Shelhigh valve, 2 points should be made.2
First, it is misleading to report on a
pulmonary valve “replacement” in this set-
ting. All 4 patients from the mentioned
group had either undergone the transannu-
lar patch procedure during tetralogy of Fal-
lot repair or commissurotomy. Likewise,
we have also gained, to date, experience
with a total of 6 patients (mean follow-up,
7.8 months; range, 2.0-13.5 months). All of
these had previous tetralogy of Fallot re-
pair. Therefore use of the Shelhigh valve in
its current form allows only for valve “im-
plantation” because the stented valve can
only self-expand and the original pulmonary
valve apparatus remains obviously in situ.
Second, we disagree with the judgment
that a reduction plasty for an enlarged main
pulmonary trunk of larger than 28 mm is
mandatory to ensure an adequate position
of the stented valve. Berdat and Carrel1
made this statement on their experience
with 1 patient only. In our experience with
6 patients (valve sizes, 23-31 mm), periop-
erative assessment included the whole right
ventricular outflow tract, dimensions of the
right ventricle to pulmonary trunk junction,
sinus of Valsalva, pulmonary trunk, and
pulmonary bifurcation. Interestingly, the fi-
nal position of the stented valve was, in our
experience, at different sites: at the level of
the pulmonary valve, just above it, and
even much more distally just in front of the
bifurcation. Therefore we would rather em-
phasize the need for both transesophageal
and epicardial echocardiographic naviga-
tion and “oversizing” of at least 2 mm to
allow for a perfect fit of this new valve
along its struts.
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Reply to the Editor:
We appreciate the comments by Schre-
iber and Lange. We believe that making a
difference between “implantation” and
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